Related Experiment Video

Updated: Jan 2, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

Sumitra Thongprasert1, Sarayut L Geater2, Dana Clement3

  • 1Medical Oncology Unit, Wattanosoth Hospital & Bangkok Hospital Chiang Mai (BDMS), Chiang Mai 50000, Thailand.

Lung Cancer Management
|December 7, 2019
PubMed
Abstract

Insights

Second-line afatinib demonstrated efficacy in non-small-cell lung cancer (NSCLC) patients with EGFR mutations. This treatment showed a 50% objective response rate and was well-tolerated, supporting its use after chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) with EGFR mutations presents treatment challenges.
  • Chemotherapy resistance necessitates effective second-line therapies.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of afatinib as a second-line treatment.
  • To assess afatinib's impact on objective response and progression-free survival in EGFR-mutated NSCLC.

Main Methods:

  • Open-label, single-arm Phase IV study.
  • 60 patients with EGFR mutation-positive NSCLC received afatinib 40 mg/day post-chemotherapy.
  • Primary endpoint: confirmed objective response.

Main Results:

  • 50% objective response rate with a median duration of 13.8 months.
  • Median progression-free survival was 10.9 months.
  • Common adverse events: diarrhea (72%), rash (28%), paronychia (23%).

Conclusions:

  • Afatinib (40 mg/day) is an effective second-line treatment for EGFR mutation-positive NSCLC.
  • Afatinib demonstrates good tolerability in this patient population.
Keywords:
EGFRafatinibsecond line

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
495
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K